China Regulatory Progress for NCX 470
Nicox Announces Positive Regulatory Feedback in China Supporting NCX 470 NDA Filing
Nicox SA's glaucoma drug NCX 470 cleared a major hurdle in China on June 18, 2026. The Chinese Center for Drug Evaluation (CDE) told Ocumension Therapeutics — Nicox's exclusive Chinese partner — that existing clinical data is enough to support a New Drug Application (NDA) filing in China, according to GlobeNewswire. The green light means Ocumension can move toward a formal submission this year.
The timing is notable. Just months ago, Nicox received similar positive feedback from the U.S. FDA ahead of a planned U.S. filing also set for Summer 2026. That means NCX 470 could enter regulatory review in the world's two largest drug markets at nearly the same time.
Two Phase 3 Trials Built the Chinese Dossier
The CDE's positive response is based on data from two pivotal trials: Mont Blanc and Denali. Both tested NCX 470 0.1% against latanoprost, the current gold-standard eye drop for glaucoma. In the Denali trial, NCX 470 lowered eye pressure by 7.9 to 10.0 mmHg from baseline. Latanoprost lowered it by 7.1 to 9.8 mmHg. NCX 470 was statistically superior at 3 of 6 measured time points, according to Benzinga.
The drug works differently from older treatments. It is a nitric oxide-donating bimatoprost analog — meaning it lowers eye pressure through two pathways at once. Standard drugs like latanoprost use only one. This dual approach is designed to help the roughly 40% of glaucoma patients who do not reach target pressure on existing therapies.
China's CDE Accepts Global Trial Data, Cutting Years Off Approval
The CDE's willingness to accept data from multi-regional clinical trials is significant. Historically, China required separate domestic trials for drug approval. Accepting the Mont Blanc and Denali data signals a shift in that stance. It could shorten NCX 470's path to Chinese patients by years, according to ADVFN.
Over 21 million people in China are estimated to have glaucoma. The Chinese glaucoma drug market is projected to reach $606.2 million by 2030. Nicox's Chief Scientific Officer Doug Hubatsch said, "This positive interaction with the Chinese Center for Drug Evaluation follows the recently announced successful NCX 470 pre-NDA meeting with the U.S. FDA. With these two outcomes in hand, we are confident the respective submissions can be achieved shortly," according to GlobeNewswire.
Safety Trade-Off: Better Pressure Control, More Eye Redness
NCX 470 does come with a notable side effect. In the Denali trial, 22.0% of patients on NCX 470 experienced conjunctival hyperemia — or red eye — compared to just 9.2% on latanoprost, according to Markets Financial Content. Critics warn this gap could hurt patient compliance over the long term, even if the pressure-lowering results are stronger.
Nicox counters that no serious ocular adverse events were recorded and that the dropout rate stayed low. Analysts at H.C. Wainwright argue the superior efficacy at peak time points is the main draw for eye specialists, even with the higher hyperemia rate. The debate will likely shape how aggressively the drug is marketed against cheaper generic alternatives.
Milestone Payments Could Wipe Out Nicox's Debt by End of 2026
The regulatory progress carries real financial weight for Nicox. Successful NDA filings in both China and the U.S. will trigger milestone payments. Combined with upfront money from its July 2025 deal with Japanese firm Kowa — worth up to €191.5 million — Nicox says it expects to fully repay its financial debts by late 2026 and extend its cash runway beyond 2027, according to UK MarketScreener.
Kowa holds the license for the U.S. and most global markets outside China, Japan, and Korea. Ocumension holds China rights. With both partners now on track to file, Nicox has moved its biggest risk from the clinic to the commercial arena — specifically, whether NCX 470 can win market share against low-cost generic latanoprost once approved.
Sentiment
NeutralPublishers
5
Articles
5
Reach
5
